Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027KT-621 BREADTH Phase 2b trial in asthma on track to ...

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

The AES meeting is a cornerstone for the epilepsy community, bringing together science, clinical innovation, and patient advocacy,” said Steven Petrou, chief scientific officer and co-founder of ...
Money Digest on MSN

You've Been Warned: These 9 Toyota Cars Have Awful Resale Value

Toyota is known for dependable, long-lasting vehicles like the Tacoma, though some of those vehicles hold their value better ...
TMCnet

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...